FDA Approves Novo Nordisk Treatment for Type 2 Diabetes in Pediatric Patients
18 June 2019 - 6:12AM
Dow Jones News
By Stephen Nakrosis
The U.S. Food and Drug Administration said Monday it approved a
treatment made by Novo Nordisk A/S to treat pediatric patients with
type 2 diabetes.
The FDA said Novo's Victoza, or liraglutide, injection is the
first non-insulin drug approved to treat type 2 diabetes in
pediatric patients since 2000. The treatment was approved for
pediatric patients 10 years or older with type 2 diabetes, and has
been approved to treat adult patients with type 2 diabetes since
2010.
Lisa Yanoff, acting director of the Division of Metabolism and
Endocrinology Products in the FDA's Center for Drug Evaluation and
Research, said: "Victoza has now been shown to improve blood sugar
control in pediatric patients with type 2 diabetes. The expanded
indication provides an additional treatment option at a time when
an increasing number of children are being diagnosed with this
disease."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 17, 2019 15:57 ET (19:57 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
